2012
Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis
Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis. Clinical Cancer Research 2012, 18: 1641-1654. PMID: 22275507, PMCID: PMC3306446, DOI: 10.1158/1078-0432.ccr-11-2324.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationDisease ProgressionHumansLung NeoplasmsMaleMiceMice, NudeMitogen-Activated Protein KinasesMolecular Targeted TherapyNeovascularization, PathologicPaclitaxelProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)QuinazolinesRas ProteinsReceptors, Vascular Endothelial Growth FactorXenograft Model Antitumor AssaysConceptsSignal-regulated kinase kinaseTumor cell proliferationCell proliferationReceptor tyrosine kinasesKinase kinaseAvailable MEK1/2 inhibitorHuman NSCLC cellsTyrosine kinaseVEGF receptor tyrosine kinasesERK phosphorylationNCI-H441MEK1/2 inhibitorApoptotic effectsAdjacent normal tissuesKinaseNSCLC cellsMEK inhibitionAntiangiogenic effectsSignalingOrthotopic human lung cancer modelAvailable potent inhibitorLung tumor growthPotent inhibitorTumor angiogenesisSelumetinib
2004
Review of epidermal growth factor receptor biology
Herbst RS. Review of epidermal growth factor receptor biology. International Journal Of Radiation Oncology • Biology • Physics 2004, 59: s21-s26. PMID: 15142631, DOI: 10.1016/j.ijrobp.2003.11.041.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorSignal transduction pathwaysSmall molecule inhibitorsTransduction pathwaysSubsequent activationReceptor tyrosine kinasesEpidermal growth factor receptor biologyTyrosine kinase phosphorylationEGFR inhibitorsTyrosine kinase receptorsIntracellular portionGrowth factor receptorCommon pharmacologic approachesEGFR activityEGFR activationExtracellular domainTyrosine kinaseKinase phosphorylationKinase receptorsCognate ligandsTransmembrane glycoproteinReceptor biologyErbB familyTumor cell linesCellular proliferation
2003
O-290 Blockade of EGFR tyrosine kinase does not predict outcome in a new orthotopic model of human lung cancer
Onn A, Isobe T, Itasaka S, Wu W, O'Reilly M, Fidler I, Herbst R. O-290 Blockade of EGFR tyrosine kinase does not predict outcome in a new orthotopic model of human lung cancer. Lung Cancer 2003, 41: s84-s85. DOI: 10.1016/s0169-5002(03)91948-9.Peer-Reviewed Original Research
2002
Targeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer
Herbst RS. Targeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer. Clinical Lung Cancer 2002, 3: s30-s38. PMID: 14720353, DOI: 10.3816/clc.2002.s.006.Peer-Reviewed Original ResearchCell lung cancerVascular endothelial growth factorProtein kinase C inhibitorLung cancerKinase C inhibitorSpecific cellular mechanismsCell cycle inhibitionEGFR tyrosine kinaseSignal transductionTyrosine kinaseKey enzymeReceptor-targeted therapyTreatment of NSCLCTumor growth delayC inhibitorEndothelial growth factorCellular mechanismsOSI-774IMC-C225Advanced NSCLCPoor prognosisMajor classesTargeted therapyNovel agentsTherapeutic improvement